OXYRASE, INC. – Trademark Portfolio
Entity Type: 03
OXYRASE, INC. owns a portfolio of 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as OXYPRAS, OXYRASE, ANASELECT, OXYSTASIS, and HOOTY MONROE. Of these, 8 are registered. The portfolio spans 4 Nice Classification classes, led by Class 1 (Chemicals) and Class 5 (Pharmaceuticals). Headquartered in ASHLAND, OH.
P.O. BOX 899
ASHLAND, OH 44805
Showing of trademarks Trademarks
Trademark Classifications
OXYRASE, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does OXYRASE, INC. have?
OXYRASE, INC. has 11 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 abandoned, 1 cancelled.
What trademark classes does OXYRASE, INC. file in?
OXYRASE, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are OXYRASE, INC.'s most well-known trademarks?
OXYRASE, INC.'s registered trademark portfolio includes well-known marks such as OXYPRAS, OXYRASE, ANASELECT, OXYSTASIS, and HOOTY MONROE. These are among 8 currently registered trademarks in the portfolio.
What is OXYRASE, INC.'s trademark registration success rate?
OXYRASE, INC. has a 73% trademark registration rate, with 8 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.